Dementia Clinical Trials

Find Dementia Clinical Trials Near You

Proving the Utility of Ultra-low Field MRI for Assessing Brain Health

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY

Small vessel disease (SVD) is a major cause of stroke and contributor to dementia cases. As work continues to develop new treatments to address the impact of SVD, new imaging techniques are needed to identify and track the progression of brain changes that occur with SVD. Magnetic Resonance Imaging (MRI) is the gold standard to diagnose poor brain health due to small vessel disease. However, current MRI systems are expensive and complex to operate, and so access is limited. Low-field MRI technology, operating at magnetic field strengths many times lower than conventional MRI, can make brain imaging much more cost-effective and accessible. However, further work is needed to develop low-field MRI towards clinically feasible assessments of brain health. The University of Aberdeen hosts a unique network of researchers and imaging technologies that is now making it possible to test and develop different low-field MRI approaches towards solving key healthcare challenges. The aim of this study is to evaluate the potential of two distinct approaches, field-cycling imaging (FCI) and ultra-low field MRI (ULF-MRI), to detect brain changes linked with small vessel disease. Automated methods will be developed to analyse images and extract measurements that detect and track progression of disease severity.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Healthy Volunteers: f
View:

• Adults ≥ 50 years old.

• Subjects who do not report problems with memory.

• Small vessel disease (Fazekas score 1 to 3).

• Suitable body habitus.

• Able to understand written and spoken English.

Locations
Other Locations
United Kingdom
Aberdeen Biomedical Imaging Centre, University of Aberdeen
RECRUITING
Aberdeen
AMT Center, Univeristy of Aberdeen
RECRUITING
Aberdeen
Contact Information
Primary
Mary Joan MacLeod
m.j.macleod@abdn.ac.uk
+44 1224 438352
Backup
Gordon D Waiter
g.waiter@abdn.ac.uk
+44 1224 438356
Time Frame
Start Date: 2025-12-17
Estimated Completion Date: 2027-05
Participants
Target number of participants: 85
Treatments
Participants with mild small vessel disease (Fazekas score = 1)
Participants with mild small vessel disease, defined by a Fazekas score of 1.
Participants with moderate small vessel disease (Fazekas score = 2)
Participants with mild small vessel disease, defined by a Fazekas score of 2.
Participants with severe small vessel disease (Fazekas score = 3)
Participants with mild small vessel disease, defined by a Fazekas score of 3.
Follow up group. Participants with moderate or severe small vessel disease (Fazekas score = 2 or 3).
Participants with moderate or severe SVD (deep white matter Fazekas 2 or 3) who will undergo an extra low-field MRI scan and will have a follow up visit at 18 months.
Related Therapeutic Areas
Sponsors
Leads: University of Aberdeen
Collaborators: NHS Grampian

This content was sourced from clinicaltrials.gov

Similar Clinical Trials